La chaîne d'options affiche les données clés des options sur actions de Bone Biologics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Bone Biologics..

Bone Biologics (NASDAQ:BBLG) Stock, Chaîne d'Options

Bone Biologics

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Bone Biologics Corp

Snowcap Compute, a semiconductor startup developing superconducting AI chips, <a href="https://www.businesswire.com/news/home/20250623688438/en/Snowcap-Compute-Launches-with-%2423-Million-Led-by-Playground-Global-to-Power-the-Next-Era-of-AI-and-Quantum-Compute">announced</a> a $23 million seed round on Monday. According to <a href="https://www.reuters.com/business/snowcap-compute-raises-23-million-superconducting-ai-chips-2025-06-23/">Reuters</a>, the company is backed by Playground Global and led by former Intel CEO Pat Gelsinger, who will also serve as board chair.
The funding round also included Cambium Capital and Vsquared Ventures.
The startup aims to create high-performance computing platforms that require significantly less power than current-generation chips. Snowcap said its superconducting architecture will deliver 25 times better performance per watt compared to existing AI systems.
Don't Miss:
<ul class="wp-block-list">
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
<h2 class="wp-block-heading">Aiming for Radical Gains in AI and Quantum Computing</h2>
Snowcap Compute's superconducting chips are designed to operate with zero electrical resistance and require cryogenic cooling to function, according to Reuters. The company said the chips are being developed to reduce electricity consumption in artificial intelligence computing, a sector facing increasing energy demands.
Nvidia&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) upcoming Rubin Ultra server, expected in 2027, is projected to consume around 600 kilowatts of power—about two-thirds of the monthly electricity use of a typical U.S. household, Reuters reported.
Snowcap CEO Michael Lafferty, formerly with Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>), told Reuters that the performance-to-power ratio of Snowcap's architecture justifies the energy spent on cooling. "We're pushing the performance level way up and pulling the power down at the same time," he said.
Snowcap plans to release a basic chip by the end of 2026. Full system deployments will follow at a later stage. The chips will be manufactured in a conventional factory using niobium titanium nitride sourced from Brazil and Canada, Reuters reported.
Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>
<h2 class="wp-block-heading">Gelsinger: Compute Needs a &#8216;Sharp Break&#8217; From Today's Power Demands</h2>
Gelsinger, who <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42275410/intel-ceo-pat-gelsinger-forced-out-by-board-analysts-cheer-potential-strategy-shift-this-move-opens-the-door">stepped down as Intel CEO</a> in December, said the industry must rethink its reliance on increasingly power-hungry chips. "A lot of data centers today are just being limited by power availability," he told Reuters.
In a LinkedIn <a href="https://www.linkedin.com/posts/patgelsinger_snowcap-compute-raises-23-million-for-superconducting-activity-7342929937462435840-U2DE/">post</a>, Gelsinger described Snowcap as "the first commercially viable superconducting compute platform," and said it delivers performance and efficiency gains across classical, AI, and quantum workloads. He called it his first public investment as general partner at Playground Global and said the company's technology could address compute bottlenecks and "push the boundaries of what is possible with silicon."
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
<h2 class="wp-block-heading">Team Includes Veterans From Nvidia, Northrop Grumman, and Google</h2>
Snowcap's founding team includes superconducting researchers Anna Herr and Quentin Herr, who previously worked at chip research firm Imed and defense contractor Northrop Grumman Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>). The team also includes former executives from Nvidia and Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>, GOOGL)) Google unit.
According to Snowcap, its architecture is engineered for high-performance AI inference and training, quantum-classical hybrid workloads, and low-latency systems.
<h2 class="wp-block-heading">Snowcap Joins Broader Push to Rethink Post-CMOS Era</h2>
Founded in 2024, Snowcap enters a growing field of startups pursuing alternatives to conventional complementary metal-oxide-semiconductor-based processors.&nbsp;
The company said its superconducting logic offers "orders-of-magnitude gains in processing speed and efficiency" and aims to support emerging compute workloads spanning AI, high-performance computing, and quantum workflows.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.

News

CDNS

GOOG

NVDA

From Power-Hungry AI to Energy Saver: Snowcap's $23M Move to Revolutionize Computing

AIMDW

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

AIMD

Texas Pacific Land (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>) has outperformed the market over the past 10 years by 40.24% on an annualized basis producing an average annual return of 51.72%. Currently, Texas Pacific Land has a market capitalization of $24.26 billion. 
Buying $100 In TPL: If an investor had bought $100 of TPL stock 10 years ago, it would be worth $6,451.34 today based on a price of $1055.44 for TPL at the time of writing.
<h3>Texas Pacific Land's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751067910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Motorola Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) has outperformed the market over the past 20 years by 27.24% on an annualized basis producing an average annual return of 35.73%. Currently, Motorola Solutions has a market capitalization of $69.63 billion. 
Buying $1000 In MSI: If an investor had bought $1000 of MSI stock 20 years ago, it would be worth $450,172.04 today based on a price of $417.01 for MSI at the time of writing.
<h3>Motorola Solutions's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751067014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) has outperformed the market over the past 10 years by 2.2% on an annualized basis producing an average annual return of 13.68%. Currently, Lululemon Athletica has a market capitalization of $29.44 billion. 
Buying $100 In LULU: If an investor had bought $100 of LULU stock 10 years ago, it would be worth $361.29 today based on a price of $235.00 for LULU at the time of writing.
<h3>Lululemon Athletica's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751066110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LULU

$100 Invested In Lululemon Athletica 10 Years Ago Would Be Worth This Much Today

ExlService Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) has outperformed the market over the past 15 years by 6.18% on an annualized basis producing an average annual return of 18.84%. Currently, ExlService Hldgs has a market capitalization of $7.13 billion. 
Buying $1000 In EXLS: If an investor had bought $1000 of EXLS stock 15 years ago, it would be worth $12,775.51 today based on a price of $43.82 for EXLS at the time of writing.
<h3>ExlService Hldgs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751065214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXLS

$1000 Invested In ExlService Hldgs 15 Years Ago Would Be Worth This Much Today

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 1.37% on an annualized basis producing an average annual return of 12.85%. Currently, HealthEquity has a market capitalization of $9.09 billion. 
Buying $1000 In HQY: If an investor had bought $1000 of HQY stock 10 years ago, it would be worth $3,276.48 today based on a price of $104.88 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751064312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today

Scott Galloway had a plan: sell his company, take $25 million, raise another $250 million, and become a billionaire. But then he stopped to think about it. &#8220;Why would I want back on this hamster wheel of stress?&#8221; he asked on a recent episode of his <a href="https://www.youtube.com/watch?v=736vqEuvNq0">podcast</a>, &#8220;Office Hours.&#8221;
<h2 class="wp-block-heading">Chasing Money, Losing Time</h2>
Galloway, a business professor, entrepreneur and <a href="https://www.benzinga.com/news/topics/25/06/45748195/i-bought-netflix-at-12-and-sold-at-10-now-its-at-1100-says-scott-galloway-hates-when-people-only-post-their-wins-online">investor</a>, said he realized the pursuit of more wealth would just cost him time, peace of mind and family moments. &#8220;I&#8217;ve been doing nothing but working for a quarter century,&#8221; he said. After hitting his personal financial target, he made a different choice: spend on what brings joy, pay people well, and give the rest away.
&#8220;I hit my number eight years ago,&#8221; he said. &#8220;And I decided there&#8217;s just no reason why I would ever need to be a billionaire.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
&#8220;Every year I look at my number,&#8221; he explained. &#8220;Anything above that number, I do one of two things: I either spend it or I give it away.&#8221;
He added, &#8220;It feels amazing to spend money and to give it away.&#8221; He owns a plane and refuses to let money prevent him from enjoying life. When friends can&#8217;t afford to join, he covers the cost himself, saying it gives him satisfaction.
<h2 class="wp-block-heading">The Billionaire Trap</h2>
His shift in mindset mirrors that of Andrew Wilkinson, a Canadian entrepreneur who told his own story in the 2024 book, &#8220;Never Enough.&#8221; Wilkinson became a billionaire after building the tech conglomerate Tiny, but eventually saw the limits of wealth.
After nearly partnering with legendary investor Charlie Munger, Wilkinson said he turned it down. The thought of chasing another level of wealth no longer appealed to him.
Both Wilkinson and Galloway reached a similar conclusion. Once you have enough, more doesn&#8217;t necessarily improve your life. In fact, it can increase stress.
Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>
Galloway recalls the fear he felt in 2008 when his first son was born during the financial crisis. &#8220;All I felt was shame and fear,&#8221; he said. &#8220;I thought, I&#8217;ve failed this kid. I don&#8217;t have enough money.&#8221; That fear stayed with him until he reached financial security.
&#8220;Happiness is not only a function of the things you have,&#8221; he said. &#8220;It&#8217;s a function of the things that you don&#8217;t have—specifically, an absence from stress.&#8221;
<h2 class="wp-block-heading">Talking About Money Matters</h2>
Galloway also wants to normalize <a href="https://www.benzinga.com/money/loud-budgeting">open conversations about money</a>. &#8220;This zeitgeist that you&#8217;re not supposed to talk about money is nothing but an effort by rich people to keep the poor and middle class down,&#8221; he said.
He encourages people to <a href="https://www.benzinga.com/personal-finance/management/25/06/45929823/the-salary-a-single-person-needs-to-live-comfortably-now-outweighs-median-annual-wages-in-all-50-states">share information about salaries</a>, taxes and <a href="https://www.benzinga.com/pro/">financial tools to help each other get ahead</a>. &#8220;Talking about it a lot gives you ideas and opportunities and can be quite cathartic,&#8221; he said.
These days, Galloway says he&#8217;s off the hamster wheel for good. He spends on joy, gives generously and says he finally feels free.
Read Next:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

Scott Galloway Reached His Financial Goal 8 Years Ago. He Says There's Just No Justification For Becoming A Billionaire

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.78% on an annualized basis producing an average annual return of 14.26%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $106.91 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 10 years ago, it would be worth $3,791.86 today based on a price of $216.97 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751063412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Marsh & McLennan Cos Stock In The Last 10 Years

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 17.33% on an annualized basis producing an average annual return of 25.82%. Currently, Intuitive Surgical has a market capitalization of $191.75 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 20 years ago, it would be worth $98,896.23 today based on a price of $535.00 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751062512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

Here's How Much $1000 Invested In Intuitive Surgical 20 Years Ago Would Be Worth Today

Emerson Radio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MSN#AMEX">MSN</a>) reported quarterly losses of $(0.11) per share. This is a 175 percent decrease over losses of $(0.04) per share from the same period last year. The company reported $1.846 million in sales this quarter. This is a 16.13 percent decrease over sales of $2.201 million the same period last year.

Earnings

Emerson Radio Q4 EPS $(0.11) Down From $(0.04) YoY, Sales $1.846M Down From $2.201M YoY

General

SNFCA

Security National Financial To Join Russell 3000 Index, Effective On June 30, 2025

Mexco Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) reported quarterly earnings of $0.30 per share. This is a 150 percent increase over earnings of $0.12 per share from the same period last year. The company reported $1.990 million in sales this quarter. This is a 10.97 percent increase over sales of $1.793 million the same period last year.

Mexco Energy Q4 EPS $0.30 Up From $0.12 YoY, Sales $1.990M Up From $1.793M YoY

In the current market session, Automatic Data Processing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) share price is at $303.50, after a 0.17% increase. Moreover, over the past month, the stock fell by 6.78%, but in the past year, went up by 28.76%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1751061620_0.png" alt="Past Year Chart" />

<h3>Comparing Automatic Data Processing P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Automatic Data Processing has a lower P/E than the aggregate P/E of 50.05 of the Professional Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751061620_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Automatic Data Processing

IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 75 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $330.000 thousand which beat the analyst consensus estimate of $305.000 thousand by 8.20 percent. This is a 11.86 percent increase over sales of $295.000 thousand the same period last year.

Earnings Beats

IGC Pharma Q4 EPS $(0.01) Beats $(0.02) Estimate, Sales $330.000K Beat $305.000K Estimate

Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) has outperformed the market over the past 15 years by 4.63% on an annualized basis producing an average annual return of 17.29%. Currently, Arch Capital Group has a market capitalization of $33.85 billion. 
Buying $1000 In ACGL: If an investor had bought $1000 of ACGL stock 15 years ago, it would be worth $10,819.65 today based on a price of $90.32 for ACGL at the time of writing.
<h3>Arch Capital Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751060713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Insider Trades

Walmart Form4 Filing Shows Walton Family Holdings Trust Sold 378,639 Shares At An Average Price Of $97.52/Share

CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.25%. Currently, CBRE Group has a market capitalization of $41.55 billion. 
Buying $1000 In CBRE: If an investor had bought $1000 of CBRE stock 5 years ago, it would be worth $3,150.54 today based on a price of $139.38 for CBRE at the time of writing.
<h3>CBRE Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751059848_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBRE

Here's How Much $1000 Invested In CBRE Group 5 Years Ago Would Be Worth Today

Stock Split

BIVI

BioVie To Implement 1-For-10 Reverse Stock Split, Effective July 7, 2025

Press Releases

Actinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer Treatment

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Bone Biologics Announces 1-for-6 Reverse Stock Split

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Files Patent Application for Bone Regeneration Technology

Bone Biologics Announces Pricing of $5.0 Million Public Offering

ATNM

BBLG

BBLGW

DRMA

NUZE

PIRS

Aditxt

Alzamend Neuro

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Oragenics

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Bone Biologics

Bone Biologics (BBLG) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL